MindMaze Therapeutics Holding SA
Company Profile
Business Description
MindMaze Therapeutics Holding SA is a Switzerland-based life sciences company specializing in precision neurology and brain health through an AI-enabled neurotechnology platform. Formed via the business combination of NeuroX Group and Relief Therapeutics, it integrates biopharmaceutical development for rare and specialty diseases with digital therapeutics, motion analytics, and proprietary devices to deliver motor and cognitive rehabilitation. Key products include MindPod, an immersive platform for brain recovery; MindMotion GO, a neurorehabilitation system for clinical and home use; Izar, a hand training peripheral for conditions like stroke and Parkinson’s; and Physilog, for 3D motion assessments and digital biomarkers. The company advances drug candidates using proprietary delivery technologies like Physiomimic and TEHCLOTM, targeting rare metabolic and dermatological diseases. With over 35,000 patients treated, multiple regulatory approvals, and a unique US CAT-3 reimbursement code, MindMaze Therapeutics Holding SA bridges biopharma and digital health, supporting care across the continuum from acute settings to home, while fostering partnerships with pharma and providers to address unmet needs in neurology.
Profitability & Growth
Profitability
Recent Year-End
Balance Sheet Snapshot
Current Ratio (MRQ)
1.20
Book Value / Share
0.25